TraC Effector Protein CRISPR System for Compact Genome Editing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current CRISPR gene editing systems, particularly those based on Cas12 proteins, face limitations in efficiency, specificity, and versatility for genome editing applications.

Innovation Solution

The development of a novel CRISPR system utilizing TraC effector proteins, which can form complexes with guide RNAs derived from transposon right elements or traditional CRISPR systems, enabling targeted DNA binding and cleavage with enhanced specificity and efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Cas12 proteins are used for genome editing, then DNA cleavage activity is achieved, but the protein size is large which limits delivery efficiency

Engineering Contradiction:
ImproveDNA cleavage activityVSAvoidprotein size
Core Design Contradiction:
ReliabilityVSWeight of moving object

Solution Approach 1:

The patent identifies and utilizes smaller Cas12 protein variants (such as Cas12f, Cas12j, and other miniaturized versions) that retain DNA cleavage functionality while having reduced molecular weights compared to traditional Cas12a/b proteins. This allows the editing machinery to be delivered more efficiently into cells while maintaining the essential nuclease activity for genome editing applications.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

2Reliability

If traditional CRISPR systems are used, then genome editing capability is achieved, but versatility is limited requiring multiple different tools for different applications

Engineering Contradiction:
Improvegenome editing capabilityVSAvoidapplication versatility
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent describes engineered CRISPR systems where a single Cas12 protein variant can perform multiple genome editing functions including but not limited to: precise DNA cleavage, base editing when fused with deaminase enzymes, prime editing when combined with reverse transcriptase, and transcriptional regulation. This multi-functional design allows researchers to accomplish various editing goals using a unified platform rather than requiring separate specialized tools for each application type.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Productivity

If Cas12 proteins with multiple functional domains are used, then DNA cleavage efficiency is improved, but system complexity increases

Engineering Contradiction:
ImproveDNA cleavage efficiencyVSAvoidsystem complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent focuses on isolating and optimizing the essential RuvC domain functionality in Cas12 proteins, removing or simplifying non-essential functional domains that contribute to complexity. By concentrating on the core nuclease activity and using streamlined protein variants with fewer auxiliary domains, the system achieves high DNA cleavage efficiency while reducing overall system complexity and ease of manipulation.

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The TraC-based CRISPR system demonstrates improved genome editing capabilities, including dual guidance mechanisms, efficient DNA cleavage, and potential for multiple genome editing applications with a single tool, while being suitable for delivery and editing in vivo due to its smaller monomeric size.

Implementation Method 1

the TraC effector protein can target and bind to a target DNA sequence under the guidance of the guide RNA

Methodology Applied
Scientific EffectComplementary base pairing:

Implementation Method 2

the TraC effector protein can target and bind to a target DNA sequence... efficient DNA cleavage

Methodology Applied
Scientific EffectDNA cleavage: Enzyme

Data Source

PatentEP4534683A1Novel crispr gene editing system
Publication Date: 2025.04.09 BEIJING QI BIODESIGN BIOTECHNOLOGY CO LTD
  • EP4534683A1 patent drawingFigure 1~2
  • EP4534683A1 patent drawingFigure 3~4
  • EP4534683A1 patent drawingFigure 5~6B

AI summary

The present invention belongs to the field of genetic engineering. Specifically, the present invention relates to a novel CRISPR gene editing system and uses thereof. More specifically, the present invention provides a TraC (intermediates between Transposon and CRISPR-Cas12) effector protein or functional variant thereof, gene editing systems based thereon and uses thereof.